Sacral neuromodulation in the golden years

Treatment outcomes in elderly 75 years and older

Authors

  • Roseanne Ferreira Department of Health Research Methods, Evidence and Impact. McMaster University https://orcid.org/0000-0001-8075-8433
  • Samuel Otis-Chapados Division of Urology, University Health Network, Toronto, Canada. https://orcid.org/0000-0003-3393-0012
  • Emad Alwashmi Division of Urology, University Health Network, Toronto, Canada. Department of Surgery, College of Medicine, Qassim University, Qassim, Saudi Arabia.
  • Naeem Bhojani 5. Division of Urology, Centre Hospitalier de l’Université de Montréal (CHUM), Montréal, QC, CA
  • Kevin C. Zorn 5. Division of Urology, Centre Hospitalier de l’Université de Montréal (CHUM), Montréal, QC, CA
  • Bilal Chughtai Department of Urology, Weill Cornell Medical College, New York, NY, USA
  • Dean S. Elterman Division of Urology, University Health Network, Toronto, Canada. https://orcid.org/0000-0003-1507-7783

DOI:

https://doi.org/10.5489/cuaj.8421

Keywords:

Sacral Neuromodulation, Overactive Bladder, Fecal incontinence, Elderly

Abstract

INTRODUCTION: Despite high prevalence and increased severity and burden of overactive bladder (OAB) and fecal incontinence (FI) in the elderly, sacral neuromodulation (SNM) is often overlooked as a potential treatment option for this demographic. In this study, we report the outcomes of SNM in patients aged 75 years or older at the time of surgery.

METHODS: We conducted a retrospective cohort study of patients who underwent SNM implantation between 2013 and 2022 performed by a single, high-volume urologist at a tertiary center. Success, complication, and adjunct therapy rates were analyzed by Fisher’s or Wilcox rank-sum test as appropriate. We compared outcomes between patients aged 75–79 years and octogenarians.

RESULTS: Of 632 patients, 50 were ≥75 years. Patients had a mean age of 78.4±2.6 years and were predominantly female (84%). The indications for SNM were 66% OAB, 16% FI, 16% non-obstructive urinary retention, and 4% pelvic pain. Within the first year, 94% of patients reported satisfaction and improvement in symptoms, while 76% continued to experience improvement beyond one year. SNM insertion led to reduced oral medication use from 68% to 24% (p<0.0001). The complication rate was 16% and mostly included device pain. No significant difference was observed in treatment success, complication, or adjunct therapy rate between age groups.

CONCLUSIONS: SNM is a safe and effective option in well-selected patients over the age of 75 years. Treatment success rate is comparable to younger cohorts. Advanced age should not preclude third-line therapy options in this population.

Downloads

Download data is not yet available.

Published

2023-10-23

How to Cite

Ferreira, R., Otis-Chapados, S., Alwashmi, E., Bhojani, N., Zorn, K. C., Chughtai, B., & Elterman, D. S. (2023). Sacral neuromodulation in the golden years: Treatment outcomes in elderly 75 years and older. Canadian Urological Association Journal, 18(2), 12–6. https://doi.org/10.5489/cuaj.8421

Issue

Section

Original Research

Similar Articles

You may also start an advanced similarity search for this article.